Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease
- 1 April 1998
- journal article
- Published by Elsevier in The Lancet
- Vol. 351 (9111) , 1221-1222
- https://doi.org/10.1016/s0140-6736(05)79311-9
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Entacapone improves motor fluctuations in levodopa‐ treated Parkinson's disease patientsAnnals of Neurology, 1997
- Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patientsJournal of Neurology, Neurosurgery & Psychiatry, 1997
- Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trialNeurology, 1997
- Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly*Clinical Pharmacology & Therapeutics, 1997
- Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatmentNeurology, 1997
- Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor FluctuationsNeurology, 1997
- Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patientsNeurology, 1994
- Catechol‐O‐methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patientsNeurology, 1993
- 3‐O‐Methyldopa and the response to levodopa in Parkinson's diseaseAnnals of Neurology, 1987